Copyright Reports & Markets. All rights reserved.

Global Cutaneous Fibrosis Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Cutaneous Fibrosis Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Immunotherapy
      • 1.4.3 Corticosteroids
      • 1.4.4 Anti-Fibrotic Drugs
      • 1.4.5 Immunoglobulins
    • 1.5 Market by Application
      • 1.5.1 Global Cutaneous Fibrosis Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals Pharmacies
      • 1.5.3 Retail Pharmacies
      • 1.5.4 Online Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Cutaneous Fibrosis Treatment Market Size
    • 2.2 Cutaneous Fibrosis Treatment Growth Trends by Regions
      • 2.2.1 Cutaneous Fibrosis Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Cutaneous Fibrosis Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Cutaneous Fibrosis Treatment Market Size by by Players
      • 3.1.1 Global Cutaneous Fibrosis Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Cutaneous Fibrosis Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Cutaneous Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Cutaneous Fibrosis Treatment Key Players Head office and Area Served
    • 3.3 Key Players Cutaneous Fibrosis Treatment Product/Solution/Service
    • 3.4 Date of Enter into Cutaneous Fibrosis Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Cutaneous Fibrosis Treatment Market Size by Type (2014-2019)
    • 4.2 Global Cutaneous Fibrosis Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Cutaneous Fibrosis Treatment Market Size (2014-2019)
    • 5.2 Cutaneous Fibrosis Treatment Key Players in North America
    • 5.3 North America Cutaneous Fibrosis Treatment Market Size by Type
    • 5.4 North America Cutaneous Fibrosis Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Cutaneous Fibrosis Treatment Market Size (2014-2019)
    • 6.2 Cutaneous Fibrosis Treatment Key Players in Europe
    • 6.3 Europe Cutaneous Fibrosis Treatment Market Size by Type
    • 6.4 Europe Cutaneous Fibrosis Treatment Market Size by Application

    7 International Players Profiles

    • 7.1 AbbVie
      • 7.1.1 AbbVie Company Details
      • 7.1.2 Company Description and Business Overview
      • 7.1.3 Cutaneous Fibrosis Treatment Introduction
      • 7.1.4 AbbVie Revenue in Cutaneous Fibrosis Treatment Business (2014-2019))
      • 7.1.5 AbbVie Recent Development
    • 7.2 Bayer
      • 7.2.1 Bayer Company Details
      • 7.2.2 Company Description and Business Overview
      • 7.2.3 Cutaneous Fibrosis Treatment Introduction
      • 7.2.4 Bayer Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.2.5 Bayer Recent Development
    • 7.3 Merck
      • 7.3.1 Merck Company Details
      • 7.3.2 Company Description and Business Overview
      • 7.3.3 Cutaneous Fibrosis Treatment Introduction
      • 7.3.4 Merck Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.3.5 Merck Recent Development
    • 7.4 Bristol-Myers Squibb
      • 7.4.1 Bristol-Myers Squibb Company Details
      • 7.4.2 Company Description and Business Overview
      • 7.4.3 Cutaneous Fibrosis Treatment Introduction
      • 7.4.4 Bristol-Myers Squibb Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.4.5 Bristol-Myers Squibb Recent Development
    • 7.5 Sanofi
      • 7.5.1 Sanofi Company Details
      • 7.5.2 Company Description and Business Overview
      • 7.5.3 Cutaneous Fibrosis Treatment Introduction
      • 7.5.4 Sanofi Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.5.5 Sanofi Recent Development
    • 7.6 Boehringer Ingelheim
      • 7.6.1 Boehringer Ingelheim Company Details
      • 7.6.2 Company Description and Business Overview
      • 7.6.3 Cutaneous Fibrosis Treatment Introduction
      • 7.6.4 Boehringer Ingelheim Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.6.5 Boehringer Ingelheim Recent Development
    • 7.7 Roche
      • 7.7.1 Roche Company Details
      • 7.7.2 Company Description and Business Overview
      • 7.7.3 Cutaneous Fibrosis Treatment Introduction
      • 7.7.4 Roche Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.7.5 Roche Recent Development
    • 7.8 GlaxoSmithKline
      • 7.8.1 GlaxoSmithKline Company Details
      • 7.8.2 Company Description and Business Overview
      • 7.8.3 Cutaneous Fibrosis Treatment Introduction
      • 7.8.4 GlaxoSmithKline Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.8.5 GlaxoSmithKline Recent Development
    • 7.9 Pfizer
      • 7.9.1 Pfizer Company Details
      • 7.9.2 Company Description and Business Overview
      • 7.9.3 Cutaneous Fibrosis Treatment Introduction
      • 7.9.4 Pfizer Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.9.5 Pfizer Recent Development
    • 7.10 Novartis
      • 7.10.1 Novartis Company Details
      • 7.10.2 Company Description and Business Overview
      • 7.10.3 Cutaneous Fibrosis Treatment Introduction
      • 7.10.4 Novartis Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
      • 7.10.5 Novartis Recent Development
    • 7.11 LEO Pharma
    • 7.12 Actelion

    8 Market Forecast 2019-2025

    • 8.1 Market Size Forecast by Product (2019-2025)
    • 8.2 Market Size Forecast by Application (2019-2025)
    • 8.3 Market Size Forecast by Regions
    • 8.4 North America
    • 8.5 Europe

    9 Analyst's Viewpoints/Conclusions

      10 Appendix

      • 10.1 Research Methodology
        • 10.1.1 Methodology/Research Approach
          • 10.1.1.1 Research Programs/Design
          • 10.1.1.2 Market Size Estimation
          • 10.1.1.3 Market Breakdown and Data Triangulation
        • 10.1.2 Data Source
          • 10.1.2.1 Secondary Sources
          • 10.1.2.2 Primary Sources
      • 10.2 Disclaimer

      Cutaneous fibrosis is the accumulation of extracellular matrix (ECM) components in the dermis, leading to compromised function and altered architecture of the dermis. Development of fibrosis occurs naturally during scar formation in wound repair or is a pathological process in pro-fibrotic diseases.

      Cutaneous fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor may be derived from activated leukocytes, recruit’s macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins by dermal fibroblasts. The goal of skin fibrosis treatment is the restore abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems.

      The prototype of fibrotic skin disease is scleroderma, which can be divided into whole body and local forms. Progressive systemic sclerosis (PSS) is a widespread connective tissue disease in which the fibrotic process affects not only the skin but also the lungs, heart, kidneys and gastrointestinal tract.

      The classification of Cutaneous Fibrosis Treatment includes Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs and Immunoglobulins. And the proportion of Immunotherapy in 2018 is about 48.94%. Cutaneous Fibrosis Treatment is widely in Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies. The proportion of Hospitals Pharmacies in 2018 is about 54.74%.Europe is the largest consumption place, with a consumption market share nearly 32.17% in 2018. Following Europe, North America is the second largest consumption place with the consumption market share of 30.35%. Market competition is intense. AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion. are the leaders of the industry. Regional players in the cutaneous fibrosis treatment market also hold significant share which makes the cutaneous fibrosis treatment market highly fragmented.
      In 2018, the global Cutaneous Fibrosis Treatment market size was 475.1 million US$ and it is expected to reach 723.7 million US$ by the end of 2025, with a CAGR of 6.2% during 2019-2025.

      This report focuses on the global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Fibrosis Treatment development in North America and Europe..

      The key players covered in this study
      AbbVie
      Bayer
      Merck
      Bristol-Myers Squibb
      Sanofi
      Boehringer Ingelheim
      Roche
      GlaxoSmithKline
      Pfizer
      Novartis
      LEO Pharma
      Actelion

      Market segment by Type, the product can be split into
      Immunotherapy
      Corticosteroids
      Anti-Fibrotic Drugs
      Immunoglobulins

      In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.

      Market segment by Application, split into
      Hospitals Pharmacies
      Retail Pharmacies
      Online Pharmacies

      In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.

      Market segment by Regions/Countries, this report covers
      North America
      Europe

      The study objectives of this report are:
      To analyze global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Cutaneous Fibrosis Treatment development in North America and Europe..
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Cutaneous Fibrosis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now